FSH formulation

Details FSH formulation FSH formulation

2006-07-07

2008-11-04

Allen, Marianne P (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S399000, C530S398000

Reexamination Certificate

active

07446090

ABSTRACT:
This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.

REFERENCES:
patent: 4496537 (1985-01-01), Kwan
patent: 4589402 (1986-05-01), Hodgen et al.
patent: 4659696 (1987-04-01), Hirai et al.
patent: 4670419 (1987-06-01), Uda et al.
patent: 4746508 (1988-05-01), Carey et al.
patent: 4758552 (1988-07-01), Gulyas et al.
patent: 4847079 (1989-07-01), Kwan
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 5087615 (1992-02-01), Chappel et al.
patent: 5128453 (1992-07-01), Arpaia et al.
patent: 5162306 (1992-11-01), Donaldson
patent: 5270057 (1993-12-01), de Meere et al.
patent: 5356876 (1994-10-01), Espey
patent: 5374620 (1994-12-01), Clark et al.
patent: 5384132 (1995-01-01), De Meere et al.
patent: 5508261 (1996-04-01), Moyle et al.
patent: 5580856 (1996-12-01), Prestrelski et al.
patent: 5639640 (1997-06-01), Reddy et al.
patent: 5650390 (1997-07-01), Samaritani et al.
patent: 5661125 (1997-08-01), Strickland
patent: 5681822 (1997-10-01), Bornstein et al.
patent: 5733572 (1998-03-01), Unger et al.
patent: 5767067 (1998-06-01), Arpaia et al.
patent: 5811096 (1998-09-01), Aleman et al.
patent: 5889110 (1999-03-01), Hutchinson et al.
patent: 5929028 (1999-07-01), Skrabanja et al.
patent: 5945187 (1999-08-01), Buch-Rasmussen et al.
patent: 6066620 (2000-05-01), McGregor et al.
patent: 6136784 (2000-10-01), L'Italien et al.
patent: 6238890 (2001-05-01), Boime et al.
patent: 6267958 (2001-07-01), Andya et al.
patent: 6440930 (2002-08-01), Rinella, Jr.
patent: 6541606 (2003-04-01), Margolin et al.
patent: 6573237 (2003-06-01), Rinella, Jr.
patent: 2003/0072803 (2003-04-01), Goldenberg et al.
patent: 1340132 (1998-11-01), None
patent: 41 17 078 (1882-11-01), None
patent: 0 318 081 (1989-05-01), None
patent: 0 448 146 (1991-09-01), None
patent: 0 652 766 (1993-07-01), None
patent: 0 603 159 (1994-06-01), None
patent: 0 853 945 (1998-07-01), None
patent: 0 920 873 (1998-12-01), None
patent: 0 891 774 (1999-01-01), None
patent: 0 668 073 (1999-04-01), None
patent: 1 191 099 (1999-06-01), None
patent: 0 736 303 (1999-08-01), None
patent: 0 974 359 (2000-01-01), None
patent: 2782455 (2000-02-01), None
patent: 839 300 (1958-08-01), None
patent: 1065127 (1967-04-01), None
patent: WO 92/21332 (1992-12-01), None
patent: WO 92/22568 (1992-12-01), None
patent: WO 93/11788 (1993-06-01), None
patent: WO 94/03198 (1994-02-01), None
patent: WO 97/04801 (1997-02-01), None
patent: WO 97/17087 (1997-05-01), None
patent: WO 98/30592 (1998-07-01), None
patent: WO 99/21534 (1999-05-01), None
Pimpalkhute et al. RAdioimmunoassay of Human FSH. Journal of Radioanalytical and Nuclear Chemistry. Abstract. vol. 103, No. 2, pp. 105-116; (1986).
Akers Michael J., “Considerations in selecting antimicrobial preservative agents for parenteral product development”, Pharmaceutical Technology, May 1984, pp. 36-46.
Akers, Michael J., “Excipient—Drug Interactions in Parenteral Formulations”, Journal of Pharmaceutical Sciences, Nov. 2002, vol. 91, No. 11, pp. 2283-2300.
Amir, Syed M. et al., “Phenol, A Potent Stimulator of Adenylate Cyclase in Human Thyroid Membranes”, Endocrine Research Communications, 8(2):83-95, 1981.
Package insert for A.P.L. (Wyeth Laboratories) dated Dec. 4, 1974.
Approved Drug and Legal Requirements, 20th Edition, 2000.
Arzneiformenlehre, Paul Heinz List, Wissenschaftliche Verlagsgellschaft mbH, Stuttgart, 4th Edition, 1985, pp. 402-407.
Baenziger, Jacques U. et al., “Pituitary Glycoprotein Hormone Oligosaccharides: Structure, Synthesis and Function of the Asparagine-Linked Oligosaccharides on Lutropin, Follitropin, and Thyrotropin”, Biochimica et Biophysica Acta, 1988, 947:287-306.
Boime, Irving et al., “Glycoprotein Hormone Structure-Function and Analog Design”, Recent Progress in Hormone Research, vol. 54, 1999, The Endocrine Society, pp. 271-289.
Burgues et al., “Subcutaneous self-administration of highly purified follicle stimulating hormone and human chorionic gonadotrophin for the treatment of male hypogonadotropic hypogonadism”, Human Reproduction, 1997, vol. 12, No. 5, pp. 980-986.
Combarnous, Yves, “Molecular Basis of the Specificity of Binding of Glycoprotein Hormones to Their Receptors”, Endocrine Reviews, 1992, vol. 13, No. 4, pp. 670-691.
CPMP Guidelines antimicrobial preservation inclusion, CPMP/CVMP/OWP/115/95, Jul. 8, 1997, pp. 1-6.
de Medeiros, S.F. et al., “Stability of Immunoreactive β-Core Fragment of hCG”, Obstetrics & Gynecology, vol. 77, No. 1, Jan. 1991, pp. 53-59.
European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP), “Note for Guidance on Maximum Shelf-life for Sterile Products for Human Use After First Opening or Following Reconstitution”, Guidance CPMP/QWP/159/96, 1999.
European Pharmacopia, 1997 (last revised version of 2001), pp. 1-6.
Extract from Handbook of Pharmaceutical Excipients, 3rd Edition, 2000, pp. 41-43.
Fiddes et al., “Structure, Expression, and Evolution of the Genes for the Human Glycoprotein Hormones”, Recent Progress in Hormone Research, 1984, vol. 40, pp. 43-78.
Fiddes et al., “The Gene Encoding the Common Alpha Subunit of the Four Human Glycoprotein Hormones”, Journal of Molecular and Applied Genetics, 1981, vol. 1, pp. 3-18.
Fransson, Jonas et al., “Solvent Effects on the Solubility and Physical Stability of Human Insulin-Like Growth Factor 1”, Pharmaceutical Research 14(5):606-12, 1997.
Frenken, L.A.M. et al., “Analysis of the Efficacy of Measures to Reduce Pain After Subcutaneous Administration of Epoetin Alfa”, Nephrology Dialysis Transplantation 9:1295-98, 1994.
Furuhashi, M. et al. “Fusing the Carboxy-Terminal Peptide of the Chorionic Gonadotropin (CG) beta Subunit to the Common alpha-Subunit: Retention of O-linked Glycosylation and Enhanced in Vivo Bioactivity of Chimeric Human CG”, Molecular Endocrinology, 1995, vol. 9, No. 1, pp. 54-63.
Garcia-Campayo, Vincenta et al., “Design of Stable Biologically Active Recombinant Lutropin Analogs”, Nature Biotechnology 15:663-67, 1997.
Gennaro et al., Remington's Pharmaceutical Sciences (18th Edition, Mack Publishing. Co., 1990, see part 8 “Pharmaceutical Preparations and their Manufacture,” pp. 1545-1569.
Gonal-F® (follitropin alfa for injection) For subcutaneous injection: Package Insert Code N1900101B, manufactured by Serono Laboratories, Inc., Randolph, MA, USA, published Sep. 1997.
Guzman et al., “The Gene Encoding Ovine Follicle-Stimulating Hormone beta: Isolation, Characterization, and Comparison to a Related Ovine Genomic Sequence”, DNA and Cell Biology, 1991, vol. 10, No. 8, pp. 593-601.
Harvey, Stewart C., “Antiseptics and Disinfectants; Fungicides; Ectoparasiticides”, The Pharmacological Basis of Therapeutics, 6thEdition, Chapter 41, 964-987, 1980.
Heikoop, Judith C. et al., “Structure-based design and protein engineering of intersubunit disulfide bonds in gonadotropins” Nature Biotechnology, Jul. 1997, vol. 15, pp. 658-662.
Hirai, T. et al., “The gene for the β subunit of porcine FSH: absence of consensus oestrogen-responsive element and presence of retroposons”, Journal of Molecular Endocrinology, 1990, vol. 5, pp. 147-158.
J. Parental Drug Assoc. Nov.-Dec. 1980, vol. 34, No. 6.
Jorgenson, Jan Trost, “Improvement of Patient Convenience in Treat

Affiliated with

Also associated with

Rating

FSH formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with FSH formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FSH formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4043164